Document Detail


New anticonvulsants in pediatrics: carbamazepine and valproate.
MedLine Citation:
PMID:  3105964     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The majority of patients with epilepsy have their first seizure during childhood and are first evaluated and diagnosed by their pediatrician. For many patients the medication selected by the pediatrician will be taken for an extended time period, perhaps even for a lifetime. The first job of the pediatrician is to be sure that the patient's recurrent attacks represent genuine epilepsy and not some other paroxysmal medical disorder such as migraine or cardiac arrhythmias. Epileptic seizures are then classified by a careful clinical description of the attacks in conjunction with the results of the physical and EEG examinations. Based on all of the information at hand, the clinician chooses the drug that is most likely to reduce or eliminate further seizures without exposing the child to unnecessary medical risk or behavioral-cognitive adverse effects. In properly selected patients, both carbamazepine and valproate are safe, physically well tolerated, and less likely to provoke chronic mental side effects than the pediatrician's "traditional" choices: phenobarbital or phenytoin. Although carbamazepine and valproate have been widely acclaimed by neurologists and epileptologists, practicing pediatricians have heretofore been less likely to initiate treatment with these drugs. Yet pediatricians have something of priceless value to offer the child with epilepsy: seizure control and a clear mind. The information in this monograph should assist the practicing pediatrician in the rational choice, initiation, and follow-up of treatment with these two excellent anticonvulsants.
Authors:
R R Clancy
Related Documents :
24702684 - Big data: the next frontier for innovation in therapeutics and healthcare.
7007674 - Van gogh's vision. digitalis intoxication?
10327384 - Psychosocial side effects of sildenafil therapy for erectile dysfunction.
19039694 - The convergent and divergent validity of the matson evaluation of drug side-effects (me...
17101054 - Evaluation of herbal cannabis characteristics by medical users: a randomized trial.
17945954 - Fragility issues of medical video streaming over 802.11e-wlan m-health environments.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Current problems in pediatrics     Volume:  17     ISSN:  0045-9380     ISO Abbreviation:  Curr Probl Pediatr     Publication Date:  1987 Mar 
Date Detail:
Created Date:  1987-05-28     Completed Date:  1987-05-28     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1272515     Medline TA:  Curr Probl Pediatr     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  133-209     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Carbamazepine / adverse effects,  therapeutic use*
Child
Child, Preschool
Electroencephalography
Epilepsy / drug therapy*
Female
Humans
Male
Substance Withdrawal Syndrome
Valproic Acid / adverse effects,  therapeutic use*
Chemical
Reg. No./Substance:
298-46-4/Carbamazepine; 99-66-1/Valproic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Factors affecting ascorbate oxidation in aqueous humor.
Next Document:  Endobronchial tuberculosis. Serial fiberoptic bronchoscopy and natural history.